share_log

SVB Securities Upgrades Elevation Oncology to Outperform, Raises Price Target to $8

SVB Securities Upgrades Elevation Oncology to Outperform, Raises Price Target to $8

SVB Securities將Elevation Oncology上調至跑贏大盤,將目標
Benzinga ·  2023/05/30 06:59

SVB Securities analyst Andrew Berens upgrades Elevation Oncology (NASDAQ:ELEV) from Market Perform to Outperform and raises the price target from $5 to $8.

SVB Securities分析師安德魯·貝倫斯將Elevation Oncology(納斯達克股票代碼:ELEV)從市場表現上調至跑贏大盤,並將目標股價從5美元上調至8美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論